{"Clinical Trial ID": "NCT00382018", "Intervention": ["INTERVENTION 1:", "(Basic CTC >= 5, Day 22 CTC >= 5, High Risk)", "Patients had increased CTC at baseline (defined as five or more CTCs per 7.5 mL WB) and >= 5 CTC at baseline (day 22). Patients would be randomized to maintain the current treatment.", "INTERVENTION 2:", "C2 weapon (Basic CTC >= 5, Day 22 CTC >= 5, High Risk)", "Patients had increased the CTC at baseline (defined as five or more CTCs per 7.5 mL WB) and >= 5 CTC at baseline (Day 22). Patients would be randomized to change treatment to another drug or combination of drugs."], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "- Breast cancer confirmed histologically", "Clinical evidence of metastatic disease (stage IV disease)", "A new metastatic disease OR progressive metastatic disease during hormonal treatment", "Meets 1 of the following criteria:", "A Measurable Disease", "* Patients with non-measurable disease who do not include bones are not eligible.", "HER-2 determined by immunohistochemistry (IHC) or fluorescent in situ hybridization (FISH)", "- HER-2 positivity is defined as IHC 3+ or FISH+", "If IHC is unknown (2+), FISH must be performed to classify the disease", "\u2022 Provide for first-line chemotherapy for metastatic diseases", "Patients with brain metastases must have a stable disease for more than 90 days after completion of pre-brain radiation therapy.", "No leptomenergic disease", "Unspecified hormonal receptor status", "CHARACTERISTICS OF PATIENTS:", "Women", "\u2022 Menopausal status not specified", "Zubrod 0-2's performance status", "No pregnancy or breast-feeding", "Negative pregnancy test", "No other malignancy in the last 5 years, except skin cancer of properly treated basal or squamous cells or stage I or II cancer currently in complete remission", "THERAPE PRIOR CONCURENT:", "See Disease Characteristics", "\u2022 Prior hormonal treatment, treatment with bisphosphonate, trastuzumab (Herceptin\u00ae) and/or bevacizumab for metastatic disease are allowed.", "Any number of exogenous hormonal therapies for metastatic diseases and/or as authorised adjuvant treatment", "At least 1 year since previous adjuvant chemotherapy", "At least 2 weeks since previous minor operation and recovered", "At least 4 weeks since previous major surgery and recovered", "No previous chemotherapy for metastatic disease", "- Concomitant hormonal treatment and/or bisphosphonate treatment are permitted", "- Licensed competitor trastuzumab and/or bevacizumab"], "Results": ["Performance measures:", "Overall survival", "From the date of registration to the date of death for any cause. Patients known for the last time to be alive are censored at the date of last contact.", "Duration: Every 3 months until progression and every 6 months for 5 years or until death", "Results 1:", "- Arm/group title: arm C1 (basic CLC >= 5, day 22 CLC >= 5, high risk)", "Patients had increased CTC at the beginning of treatment (defined as five CTCs or more by 7.5 mL WB) and >= 5 CTC at the first follow-up (day 22). Patients would be randomized to maintain the current treatment.", "Total number of participants analysed: 64", "Median (95% confidence interval)", "Unit of measure: month 10.7 (9.1 to 14.8)", "Results 2:", "- Arm/group title: arm C2 (basic CTC >= 5, day 22 CTC >= 5, high risk)", "- Arm/group description: Patients had increased the CLC at baseline (defined as five or more CLCs per 7.5 mL WB) and >= 5CTC at baseline (Day 22). Patients would be randomized to change their treatment to another drug or combination of drugs.", "Total number of participants analysed: 59", "Median (95% confidence interval)", "Unit of measurement: months 12.5 (8.4 to 16.3)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/161 (0.00 per cent)", "Other gastro-intestinals 0/161 (0.00 %)", "Dehydration 0/161 (0.00 %)", "Renal/genitorial-Other 0/161 (0.00 %)", "Adverse Events 2:", "Total: 1/64 (1.56%)", "Gastrointestinal-Other 1/64 (1.56%)", "Dehydration 1/64 (1.56%)", "Renal/genitorial-Other 1/64 (1.56%)"]}